Bárbara Ramos

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Adrian Wagg, Billy Franks, Bárbara Ramos et al. · Canadian Urological Association Journal · 2015 · 119 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Patient-physician discordance in assessment of adherence to inhaled controller medication: a cross-sectional analysis of two cohorts

Cristina Jácome, Ana Margarida Pereira, Rute Almeida et al. · BMJ Open · 2019 · 29 citations · Full text

Pharmacy, Internal Medicine, Pharmaceutical Compliance +14

The impact of weight loss beyond lung function: benefit with respect to asthma outcomes

Lília Maia Santos, Bárbara Ramos, João Almeida et al. · Pulmonology · 2019 · 17 citations · Full text

Medicine, Surgery, Outcomes Research +16

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

Sender Herschorn, Jameel Nazir, Bárbara Ramos et al. · Canadian Urological Association Journal · 2017 · 14 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada

Zalmaï Hakimi, Jameel Nazir, Charles McCrea et al. · Journal of Medical Economics · 2017 · 13 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17